key: cord-0692581-3vuuo5wh
authors: Planas, Delphine; Veyer, David; Baidaliuk, Artem; Staropoli, Isabelle; Guivel-Benhassine, Florence; Rajah, Maaran Michael; Planchais, Cyril; Porrot, Françoise; Robillard, Nicolas; Puech, Julien; Prot, Matthieu; Gallais, Floriane; Gantner, Pierre; Velay, Aurélie; Le Guen, Julien; Kassis-Chikhani, Najibi; Edriss, Dhiaeddine; Belec, Laurent; Seve, Aymeric; Péré, Hélène; Courtellemont, Laura; Hocqueloux, Laurent; Fafi-Kremer, Samira; Prazuck, Thierry; Mouquet, Hugo; Bruel, Timothée; Simon-Lorière, Etienne; Rey, Felix A.; Schwartz, Olivier
title: Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
date: 2021-05-27
journal: bioRxiv
DOI: 10.1101/2021.05.26.445838
sha: 53e73f706e5ff9a5ba8a4d78d3ccefddfd804a76
doc_id: 692581
cord_uid: 3vuuo5wh

The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India1–6. It has since then become dominant in some indian regions and further spread to many countries. The lineage includes three main subtypes (B1.617.1, B.1617.2 and B.1.617.3), which harbour diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential. B.1.617.2 is believed to spread faster than the other versions. Here, we isolated infectious B.1.617.2 from a traveller returning from India. We examined its sensitivity to monoclonal antibodies (mAbs) and to antibodies present in sera from COVID-19 convalescent individuals or vaccine recipients, in comparison to other viral lineages. B.1.617.2 was resistant to neutralization by some anti-NTD and anti-RBD mAbs, including Bamlanivimab, which were impaired in binding to the B.1.617.2 Spike. Sera from convalescent patients collected up to 12 months post symptoms and from Pfizer Comirnaty vaccine recipients were 3 to 6 fold less potent against B.1.617.2, relative to B.1.1.7. Sera from individuals having received one dose of AstraZeneca Vaxzevria barely inhibited B.1.617.2. Thus, B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.

SARS-CoV-2 variants of concern (VOCs) with mutations increasing inter-individual transmission or allowing immune evasion have supplanted ancestral strains [7] [8] [9] [10] . While the mutations have arisen in different viral proteins, of particular interest is the Spike protein, which promotes viral binding to the ACE2 receptor, mediates viral fusion and entry, and is targeted by neutralizing antibodies 10, 11 . The first identified variant included the D614G mutation which enhanced viral infectivity 7,10,12 . VOC then appeared in multiple countries. The B.1.1.7 variant was first identified in the UK, B.1.351 in South Africa and the P.1 lineage in Brazil 7-10, [13] [14] [15] . They harbour mutations that enhance Spike affinity to ACE2, such as N501Y, which is present in the three variants and K417N/T found in B.1.351 and P.1 10, [16] [17] [18] [19] [20] [21] . Antibody escape mutations in the RBD include E484K found in B.1.351 and P.1 10, [16] [17] [18] [19] [20] [21] . Another variant termed B.1.247/B.1.429 was originally detected in California. It lacks the E484K substitution and carries a different set of mutations in the NTD (S13I, W152C) and RBD (L452R). The L452R mutation reduces or abolishes neutralization by some monoclonal antibodies (mAb) or sera from convalescent persons or vaccine recipients [22] [23] [24] [25] .

Neutralizing antibodies also target non-RBD Spike epitopes, particularly in the NTD 26 . The role of the NTD during viral entry is not fully understood. It has been proposed to recognize sugar moieties upon initial binding and might be involved in pre-fusion to post-fusion transition of the Spike 27 . Some mAbs targeting the NTD may exhibit high neutralization potency without preventing Spike binding to ACE2 26, 27 . These non-RBD antibodies are highly prevalent and may represent more than 80% of the anti-Spike IgG response, even if 90% of the neutralizing activity targets the RBD 17, 27 . VOC contain changes in the NTD that have been associated with antibody escape 10, 26, 28 Here, we assessed the sensitivity of an authentic B.1.617.2 isolate to various mAbs targeting the NTD and the RBD of the Spike, including 4 clinically approved therapeutic antibodies. We also examined the neutralization potency of sera from convalescent individuals and vaccine recipients, demonstrating that the variant has indeed acquired a degree of resistance to them.

We isolated the B.1.617.2 variant from a nasopharyngeal swab of a symptomatic individual, a few days upon his return to France from India. The virus was amplified by two passages on Vero E6 cells.

Sequences of the swab and the outgrown virus were identical and identified the B.1.617.2 variant (GISAID accession ID: EPI_ISL_2029113) (Fig. 1a) . In particular, the Spike protein contained 9 mutations, when compared to the D614G strain (belonging to the basal B.1 lineage) used here as a reference, including five mutations in the NTD (T19R, G142D, Δ156, Δ157, R158G), two in the RBD (L452R, T478K), one mutation close to the furin cleavage site (P681R) and one in the S2 region (D950N) (Fig. 1a) . Viral stocks were titrated using S-Fuse reporter cells and Vero cells 21, 31 . S-Fuse cells are convenient for rapid viral titration and measurement of neutralizing antibodies. They generate a GFP signal as soon as 6 hours post infection and the number of GFP+ cells correlates with the viral inoculum 31 21 . Viral titers were similar in the two target cells and reached 10 5 to 10 6 infectious units/ml. Large syncytia were observed in B.1.617.2-infected Vero and S-Fuse cells (Fig. S1 ). As expected, the syncytia were positive for Spike staining (Fig. S1 ). Future work will help determining whether B.1.617.2 is more fusogenic than D614G or other variants, as suggested here by the large size of B.1.617.2-induced syncytia.

To contextualize the B.1.617.2 isolate reported here, we inferred a global phylogeny subsampling the diversity of SARS-CoV-2 sequences available on the GISAID EpiCoV database (Fig. 1) Upon inspection, the locations of the spike mutations in the B.1.617.2 variant showed a similar overall distribution to those that appeared in other VOC. In particular, in addition to the D614G mutation common to all current strains, the D950N mutation mapped to the trimer interface (Fig. 2a) , suggesting a potential contribution in regulating Spike dynamics, as has been shown with the D614G mutation 10 .

As with other VOC, a number of mutations in B.1.617.2 cluster in the NTD (Fig. 2b) Importantly, all these altered residues lie in the NTD "supersite" that is the target of the most potently anti-NTD neutralizing antibodies 28 . In the RBD, examining the distribution of all mutations appearing in VOC detected so far indicates that they all map to the periphery of the ACE2 binding surface (Fig.   2c ), suggesting that the virus accumulates mutations there in order to reduce or avoid antibody binding while maintaining binding to ACE2. For instance, the L452R mutation found in B.1.617.2 impairs neutralization by antibodies 22 23,24 25 and is located at this periphery. The only mutation within the ACE2 patch is at location 501, which increases the affinity of the RBD for ACE2 and is also involved in antibody escape 10 33 34 . The RBD mutation T478K in the RBD is unique to B.1.617.2 and falls within the epitope region of potent neutralizing mAbs categorized as "Class 1" (Fig. 2c) 35 . This mutation at location 478 is in proximity of the well characterized E484K mutation known to facilitate antibody escape 10 . These observations prompted us to analyze the neutralization potential of well characterized monoclonal antibodies, as well as sera from convalescents and vaccinees, against the B.1.617.2 variant.

We assessed the sensitivity of B.1.617.2 to a panel of human mAbs using the S-Fuse assay. We tested four clinically approved antibodies, Bamlanivimab (LY-CoV555), Etesevimab (LY-CoV016), Casirivimab Three out of the four mAbs inhibited B.1.617.2, whereas RBD-85 was inactive (Fig. 3a) . The four anti-NTD mAbs were globally less efficient than the anti-RBD mAbs. They all inhibited D614G, with high IC50 (1-60 µg/mL) (Fig. 3a) . Three out of the four anti-NTD antibodies totally lost any activity against (Fig. 3b) . Altogether, these results indicate that the escape of B.1.617.2 and other variants to neutralization is due to a reduction or loss of binding of the antibodies to their target.

We examined the neutralization ability of sera from convalescent subjects. We first selected samples from 56 donors in a cohort of infected individuals from the French city of Orléans. All individuals were diagnosed with SARS-CoV-2 infection by RT-qPCR or serology and included critical, severe, and mildto-moderate COVID-19 cases (Table S1) We asked whether this neutralization profile was maintained for longer periods of time. We analyzed sera from 48 individuals from another cohort of RT-qPCR-confirmed health care workers from Strasbourg University Hospitals who experienced mild disease [40] [41] [42] . The samples were collected at a later time point (M12), with a median of 330 days (range 144-383) POS (Table S1) We then classified the cases as neutralizers (defined as harboring neutralizing antibodies detectable at the first serum dilution of 1/30) and non-neutralizers, for the different viral variants and the two cohorts (Fig. 4b) (Fig. 4b) .

Altogether, these results indicate that B.1.617.2 displays enhanced resistance to neutralization by sera from convalescent individuals, particularly one year after infection.

We next asked whether vaccine-elicited antibodies neutralized B.1.617.2, in individuals that were not previously infected with SARS-CoV-2. We thus selected 28 individuals from a cohort of vaccinated health care workers established in Orléans. The characteristics of vaccinees are depicted in Table S2 . We also classified the vaccine recipients as neutralizers (with neutralizing antibodies detectable at 1/30 dilution) and non-neutralizers, for the four viral strains (Fig. 4c,d) These results are in line with the real-world efficacy of the two vaccines. The Pfizer vaccine is known to be protective against asymptomatic and symptomatic infections, including severe diseases, induced by B.1.1.7 and B.1.351, as described for instance in the UK, Israel and South Africa [46] [47] [48] In contrast, the efficacy of a two-dose regimen of AstraZeneca against mild-to-moderate disease dropped to 10% in South Africa, where the B.1.351 variant circulates 49 . Altogether, our results suggest that a single dose of AstraZeneca vaccine will not display an optimal protection against B.1.617.2.

After We studied here the cross-reactivity of mAbs to pre-existing SARS-CoV-2 viruses, sera from long-term convalescent individuals and recent vaccine recipients against B.1.617.2. We used an authentic clinical viral isolate, rather than pseudovirus particles, to assess viral sensitivity to neutralizing antibodies. We Table S3 .

3D representation of mutations on B1.617.2 and other variants to the Spike surface. Panels in Fig. 2 were prepared with The PyMOL Molecular Graphics System, Version 2.1 Schrödinger, LLC. The atomic model used (PDB:6XR8) has been previously described 55 .

S-Fuse neutralization assay. U2OS-ACE2 GFP1-10 or GFP 11 cells, also termed S-Fuse cells, become GFP+ when they are productively infected by SARS-CoV-2 31 21 . Cells were tested negative for mycoplasma. Cells were mixed (ratio 1:1) and plated at 8x10 3 per well in a μClear 96-well plate (Greiner Bio-One). The indicated SARS-CoV-2 strains were incubated with mAb, sera or nasal swabs at the indicated concentrations or dilutions for 15 minutes at room temperature and added to S-Fuse cells.

The nasal swabs and sera were heat-inactivated 30 min at 56°C before use. 18 hours later, cells were fixed with 2% PFA, washed and stained with Hoechst (dilution 1:1,000, Invitrogen). Images were acquired with an Opera Phenix high content confocal microscope (PerkinElmer). The GFP area and the number of nuclei were quantified using the Harmony software (PerkinElmer). The percentage of neutralization was calculated using the number of syncytia as value with the following formula: 100 x (1 -(value with serum -value in "non-infected")/(value in "no serum" -value in "non-infected")).

Neutralizing activity of each serum was expressed as the half maximal effective dilution (ED50). ED50 values (in µg/ml for mAbs and in dilution values for sera) were calculated with a reconstructed curve using the percentage of the neutralization at the different concentrations. We previously reported a correlation between neutralization titers obtained with the S-Fuse assay and a pseudovirus neutralization assay 56 . Kruskal-Wallis or Friedman test with Dunn's multiple comparison was performed between each viral strain. b. Each subject was arbitrarily defined as "neutralizer" (in blue) when a neutralizing activity was detected at the first (1/30) serum dilution or "non-neutralizer" (in grey) when no activity was detected.

The numbers indicate the % of neutralizers. c. ED50 of neutralization of the four viral isolates. Sera from Pfizer vaccinated recipients were sampled at week 8 (W8) and W16 post-vaccination (W5 and W13 post second dose (n=16 and n=13, respectively). Sera from AstraZeneca vaccinated recipients were sampled at W10 post-vaccination (n=12). Data are mean from two independent experiments.

The dotted line indicates an ED50 of 30. A two-sided Friedman test with Dunn's multiple comparison was performed between each viral strain at the different time points. d. Each subject was arbitrarily defined as "neutralizer" (in blue) when a neutralizing activity was detected at the 1/30 serum dilution or "non-neutralizer" (in grey) when no activity was detected. The numbers indicate the % of neutralizers. 

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies

SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

Neutralization potential of Covishield vaccinated individuals against B.1.617.1. Biorxiv, 2021

Structural and Functional Analysis of the D614G SARS-CoV-2

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Sixteen novel lineages of SARS-CoV-2 in South Africa

The variant gambit: COVID-19's next move

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

The effect of spike mutations on SARS-CoV-2 neutralization

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. Biorxiv

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

SARS-CoV-2 Variant Classifications and Definitions

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

Syncytia formation by SARS-CoV-2 infected cells

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Neutralizing monoclonal antibodies for treatment of COVID-19

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Sex differences in the decline of neutralizing antibodies to SARS-CoV-2. medRxiv

Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. medRxiv

Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

COVID-19 dynamics after a national immunization program in Israel

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Variants distribution of cases

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Global initiative on sharing all influenza data -from vision to reality

Nextstrain: real-time tracking of pathogen evolution

Distinct conformational states of SARS-CoV-2 spike protein

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Efficient generation of human IgA monoclonal antibodies

We thank Nicoletta Casartelli for critical reading of the manuscript and Pablo Guardado Calvo for discussion. We thank patients who participated to this study, members of the Virus and Immunity Unit for discussions and help, Nathalie Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis. The Opera system was co-funded by Institut Pasteur and the Région ile de